Latest News

OliX Pharmaceuticals Expands Ocular Disease Pipeline; Adds OLX304A for the Treatment of Retinitis Pigmentosa

SUWON, South Korea, May 9, 2019 /PRNewswire/ -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a lea...

2019-05-10 09:24 723

OliX Pharmaceuticals Announces The Ophthalmologist Demetrios G. Vavvas, M.D., Ph.D., to join Scientific Advisory Board

SUWON, South Korea, April 22, 2019 /PRNewswire/ -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a l...

2019-04-22 13:32 838

Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD

- License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel...

2019-03-18 23:58 786

OliX Announces Clinical Candidate Nomination for the Treatment of Geographic Atrophy

SUWON, South Korea, Jan. 18, 2019 /PRNewswire/ -- OLX10020, a cell-penetrating asymmetric siRNA ("...

2019-01-18 14:50 577

OliX, a RNAi therapeutics developer, gets approval for KOSDAQ listing

SUWON, South Korea, July 23, 2018 /PRNewswire/ -- OliX Pharmaceuticals, Inc., a leading developer o...

2018-07-23 14:42 536